Cloning and sequencing of human β(III)-tubulin cDNA: Induction of β(III) isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1395, Issue 2, 1998, Pages 237-245

  Ranganathan, Sulabha ^a   Dexter, Dwayne W ^a   Benetatos, Christopher A ^a   Hudes, Gary R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Drug resistance; Microtubule dynamics; Tubulin isotype

Indexed keywords

ANTIMITOTIC AGENT; BETA TUBULIN; ESTRAMUSTINE; PACLITAXEL; VINBLASTINE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN VARIANT; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DRUG RESISTANCE; ESTRAMUSTINE; HUMANS; MALE; MICROTUBULES; MOLECULAR SEQUENCE DATA; PACLITAXEL; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUBULIN; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0032554076     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(97)00168-1     Document Type: Article

References (37)

1. Amato R.J., Logothetis C.J., Dexeus F.H., Stella A., Kilbourn R.G., Fritz K. Preliminary results of phase II trial of estramustine and vinblastine for patients with progressive hormone-refractory prostate carcinoma (abstract). Proc. Am. Assoc. Cancer Res. 32:1992;186.
2. Hudes G.R., Greenberg R., Krigel R.L., Fox S., Scher R., Litwin S., Watts P., Speicher L., Tew K., Comis R. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer. J. Clin. Oncol. 10:1992;1754-1761.
3. Hudes G.R., Nathan F., Khater C., Haas N., Cornfield M., Giantonio B., Greenberg R., Gomella L., Litwin S., Ross E., Roethke S., McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 15:1997;3156-3163.
4. Seidman A., Scher H.I., Petrylak D., Dershaw D.D., Curley T. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J. Urol. 147:1992;931-934.
5. Gottesman M.M., Pastan I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263:1988;12163-12166.
6. Cabral F., Sobel M.E., Gottesman M.M. CHO mutants resistant to colchicine, Colcemid, or Griseofulvin have an altered β-tubulin. Cell. 20:1980;29-36.
7. Sullivan K.F. Structure and utilization of tubulin isotypes. Ann. Rev. Cell. Biol. 4:1988;687-716.
8. Banerjee A., Roach M.C., Trcka P., Luduena R.F. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin. J. Biol. Chem. 265:1990;1794-1799.
9. III isotypes enhances taxol induced microtubule assembly. Cell Struct. Funct. 18:1993;173-182.
10. Panda D., Miller H.P., Banerjee A., Luduena R.F., Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl. Acad. Sci. U.S.A. 91:1994;11358-11362.
11. Lobert S., Frankfurter A., Correia J.J. Binding of vinblastine to phosphocellulose-purified and αβ-class III tubulin: The role of nuclecotides and β-tubulin isotypes. Biochemistry. 34:1995;8050-8060.
12. Haber M., Burkhart C.A., Regl D.L., Madafiglio J., Norris M.D., Horwitz S.B. Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. 270:1995;31269-31275.
13. P. Giannakakou, D. Sackett, Y.K. Kang, A.T. Fojo, M. Poruchynsky, Tubulin from paclitaxel (PTX) resistant human ovarian carcinoma cell lines demonstrates altered response to drug, in vivo and in vitro, Proceedings of the AACR 87th Annual Meeting, 1996, vol. 37 (abstract #2176).
14. M.C. Mallarino, G.E. Duran, C. Dumontet, M. Cluck, A. Mangili, B.I. Sikic, The spectrum of resistance to paclitaxel in human sarcoma and breast cancer cells selected with and without the multidrug resistance (MDR-I) modulator PSC 833, Proceedings of the AACR 87th Annual Meeting, 1996, vol. 37 (abstract #2987).
15. IVa, tubulin isotypes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 56:1996;2584-2589.
16. S. Ranganathan, C.A. Benetatos, P.J. Colarusso, D.W. Dexter, G.R. Hudes, Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells, in press.
17. Sullivan K.F., Cleveland D.W. Identification of conserved isotype-defining variable region sequences for four vertebrate β-tubulin polypeptide classes. Cell Biol. 83:1986;4327-4331.
18. Chomczynski P., Sacchi M. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
19. Skehan P., Stoneng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
21. Banerjee A., Roach M.C., Wall K., Lopata M., Cleveland D., Luduena R.F. A monoclonal antibody against the type II isotope of β-tubulin. Preparation of isotypically altered tubulin. J. Biol. Chem. 263:1988;3029-3034.
22. IV tubulin dimers from bovine brain. J. Biol. Chem. 267:1992;5625-5630.
23. Alexander J.E., Hunt D.F., Lee M.K., Shabanowitz J., Michel H., Berlin S.C., MacDonald T.L., Sundberg R.J., Rebhun L.I., Frankfurter A. Characterization of post-translational modifications in neuron-specific class III β-tubulin by mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4685-4689.
24. Hoyle H.D., Raff E.C. Two Drosophilia beta isoforms are not functionally equivalent. J. Cell. Biol. 111:1990;1009-1026.
25. Mitchison T.J., Kirschner M.W. Dynamic instability of microtubule growth. Nature. 312:1984;237-242.
26. Margolis R.L., Wilson L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell. 13:1978;1-8.
27. Derry W.B., Wilson L., Khan I.A., Luduena R.F., Jordan M.A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes. Biochemistry. 36:1997;3554-3562.
28. Jordan M.A., Thrower D., Wilson L. Mechanism of cell proliferation by vinca alkaloids. Cancer Res. 51:1991;2212-2222.
29. Toso R.J., Jordan M.A., Farrell K.W., Matsumoto B., Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry. 32:1993;1285-1293.
30. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9552-9556.
31. Dhamodharan R., Jordan M.A., Thrower D., Wilson L., Wadsworth P. Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol. Biol. Cell. 6:1995;1215-1229.
32. Jordan M.A., Thrower D., Wilson L. Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles: Implications for the role of microtubule dynamics in mitosis. J. Cell Sci. 102:1992;401-416.
33. Panda D., Daijo J.E., Jordan M.A., Wilson L. Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-Colchicine complex. Biochemistry. 34:1995;9921-9929.
34. Ranganathan S., Salazar H., Benetatos C.A., Hudes G.R. Immunohistochemical analysis of β-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate. 30:1997;263-268.
35. Yen T.J., Gay D.A., Pachter J.S., Cleveland D.W. Autoregulated changes in stability of polyribosome-bound β-tubulin mRNAs are specified by the first 13 translated mucleotides. Mol. Cell. Biol. 8:1988;1224-1235.
36. Cleveland D.W. Autoregulated control of tubulin synthesis in animal cells. Curr. Opin. Cell Biol. 1:1989;10-14.
37. Theodorakis N.G., Cleveland D.W. Physical evidence for cotranslational regulation of β-tubulin mRNA degradation. Mol. Cell. Biol. 12:1992;791-799.